Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
Health Sciences Research, Division of Biostatistics, Mayo Clinic, Scottsdale, Arizona.
Breast J. 2020 Sep;26(9):1760-1764. doi: 10.1111/tbj.13812. Epub 2020 Apr 15.
We investigated adverse events (AEs) and clinical outcomes for proton beam therapy (PBT) after breast-conserving surgery (BCS) for breast cancer. From 2012 to 2016, 82 patients received PBT in the prospective multi-institutional Proton Collaborative Group registry. AEs were recorded prospectively at each institution. Median follow-up was 8.1 months. Median dose was 50.4 Gy in 28 fractions. Most patients received a lumpectomy bed boost (90%) and regional nodal irradiation (RNI)(83%). Six patients (7.3%) experienced grade 3 AEs (5 with dermatitis, 5 with breast pain). Body mass index (BMI) was associated with grade 3 dermatitis (P = .015). Fifty-eight patients (70.7%) experienced grade ≥2 dermatitis. PBT including RNI after BCS is well-tolerated. Elevated BMI is associated with grade 3 dermatitis.
我们研究了保乳手术后（BCS）行质子束治疗（PBT）的不良事件（AEs）和临床结局。2012 年至 2016 年，82 例患者在质子协作组前瞻性多机构注册研究中接受了 PBT。各机构前瞻性地记录了 AEs。中位随访时间为 8.1 个月。中位剂量为 28 次分割的 50.4Gy。大多数患者接受了肿瘤床加量（90%）和区域淋巴结照射（RNI）（83%）。6 例（7.3%）发生 3 级 AEs（5 例放射性皮炎，5 例乳房疼痛）。体质指数（BMI）与 3 级放射性皮炎相关（P=.015）。58 例（70.7%）患者发生了≥2 级放射性皮炎。BCS 后行 PBT 包括 RNI 耐受性良好。BMI 升高与 3 级放射性皮炎相关。
